Safety In 20 Phase II Patients Enabled Testing In 1,300 People.

Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.

Souce: PHARMA INTELLIGENCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.